Interleukin 34: A new modulator of human and experimental inflammatory bowel disease

Clinical Science

Volumn 129, Issue 3, 2015, Pages 281-290

  Zwicker, Stephanie ^a   Martinez, Gisele L ^a   Bosma, Madeleen ^a   Gerling, Marco ^a   Clark, Reuben ^a   Majster, Mirjam ^a   Söderman, Jan ^b   Almer, Sven ^a,c   Boström, Elisabeth A ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b RYHOV COUNTY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Colon epithelial cells; CSF 1; IBD; IL 34; Intestine; Macrophage

Indexed keywords

COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 34; TUMOR NECROSIS FACTOR ALPHA; INTERLEUKIN DERIVATIVE; INTERLEUKIN-34, HUMAN; INTERLEUKIN-34, MOUSE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COLON; CONTROLLED STUDY; CROHN DISEASE; EXPERIMENTAL COLITIS; EXPERIMENTAL INFLAMMATORY BOWEL DISEASE; HOMEOSTASIS; HUMAN; HUMAN CELL; HUMAN TISSUE; ILEUM; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE EPITHELIUM CELL; LAMINA PROPRIA; MACROPHAGE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; ANIMAL; IMMUNOLOGY; METABOLISM; ULCERATIVE COLITIS;

ANIMALS; COLITIS, ULCERATIVE; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKINS; MACROPHAGES; MICE; NF-KAPPA B; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937511055     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20150176     Document Type: Article

References (42)

1. Krishnan, K., Arnone, B. and Buchman, A. (2011) Intestinal growth factors: potential use in the treatment of inflammatory bowel disease and their role in mucosal healing. Inflamm. Bowel Dis. 17, 410-422.
2. Ordas, I., Eckmann, L., Talamini, M., Baumgart, D.C. and Sandborn, W.J. (2012) Ulcerative colitis. Lancet 380, 1606-1619.
3. Baumgart, D.C. and Sandborn, W.J. (2012) Crohn's disease. Lancet 380, 1590-1605.
4. Chow, A., Brown, B.D. and Merad, M. (2011) Studying the mononuclear phagocyte system in the molecular age. Nat. Rev. Immunol. 11, 788-798.
5. van Furth, R., Cohn, Z.A., Hirsch, J.G., Humphrey, J.H., Spector, W.G. and Langevoort, H.L. (1972) The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull. World Health Organ. 46, 845-852.
6. Hettinger, J., Richards, D.M., Hansson, J., Barra, M.M., Joschko, A.C., Krijgsveld, J. and Feuerer, M. (2013) Origin of monocytes and macrophages in a committed progenitor. Nat. Immunol. 14, 821-830.
7. Anderson, K.L., Smith, K.A., Conners, K., McKercher, S.R., Maki, R.A. and Torbett, B.E. (1998) Myeloid development is selectively disrupted in PU.1 null mice. Blood 91, 3702-3710.
8. Smythies, L.E., Sellers, M., Clements, R.H., Mosteller-Barnum, M., Meng, G., Benjamin, W.H., Orenstein, J.M. and Smith, P.D. (2005) Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115, 66-75.
9. Bain, C.C., Scott, C.L., Uronen-Hansson, H., Gudjonsson, S., Jansson, O., Grip, O., Guilliams, M., Malissen, B., Agace, W.W. and Mowat, A.M. (2013) Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol. 6, 498-510.
10. Rugtveit, J., Nilsen, E.M., Bakka, A., Carlsen, H., Brandtzaeg, P. and Scott, H. (1997) Cytokine profiles differ in newly recruited and resident subsets of mucosal macrophages from inflammatory bowel disease. Gastroenterology 112, 1493-1505.
11. Vivinus-Nebot, M., Frin-Mathy, G., Bzioueche, H., Dainese, R., Bernard, G., Anty, R., Filippi, J., Saint-Paul, M.C., Tulic, M.K., Verhasselt, V. et al. (2014) Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 63, 744-752.
12. Van Deventer, S.J. (1997) Tumour necrosis factor and Crohn's disease. Gut 40, 443-448.
13. Dai, X.M., Ryan, G.R., Hapel, A.J., Dominguez, M.G., Russell, R.G., Kapp, S., Sylvestre, V. and Stanley, E.R. (2002) Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 99, 111-120.
14. Lin, H., Lee, E., Hestir, K., Leo, C., Huang, M., Bosch, E., Halenbeck, R., Wu, G., Zhou, A., Behrens, D. et al. (2008) Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science 320, 807-811.
15. Wei, S., Nandi, S., Chitu, V., Yeung, Y.G., Yu, W., Huang, M., Williams, L.T., Lin, H. and Stanley, E.R. (2010) Functional overlap but differential expression of CSF-1 and IL-34 in their CSF-1 receptor-mediated regulation of myeloid cells. J. Leukoc. Biol. 88, 495-505.
16. Ma, X., Lin, W.Y., Chen, Y., Stawicki, S., Mukhyala, K., Wu, Y., Martin, F., Bazan, J.F. and Starovasnik, M.A. (2012) Structural basis for the dual recognition of helical cytokines IL-34 and CSF-1 by CSF-1R. Structure 20, 676-687.
17. Nandi, S., Gokhan, S., Dai, X.M., Wei, S., Enikolopov, G., Lin, H., Mehler, M.F. and Stanley, E.R. (2012) The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev. Biol. 367, 100-113.
18. Wang, Y., Szretter, K.J., Vermi, W., Gilfillan, S., Rossini, C., Cella, M., Barrow, A.D., Diamond, M.S. and Colonna, M. (2012) IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat. Immunol. 13, 753-760.
19. Chemel, M., Le Goff, B., Brion, R., Cozic, C., Berreur, M., Amiaud, J., Bougras, G., Touchais, S., Blanchard, F., Heymann, M.F. et al. (2012) Interleukin 34 expression is associated with synovitis severity in rheumatoid arthritis patients. Ann. Rheum. Dis. 71, 150-154.
20. Ciccia, F., Alessandro, R., Rodolico, V., Guggino, G., Raimondo, S., Guarnotta, C., Giardina, A., Sireci, G., Campisi, G., De Leo, G. et al. (2013) IL-34 is overexpressed in the inflamed salivary glands of patients with Sjögren's syndrome and is associated with the local expansion of pro-inflammatory CD14brightCD16+ monocytes. Rheumatology 52, 1009-1017.
21. Bostrom, E.A. and Lundberg, P. (2013) The newly discovered cytokine IL-34 is expressed in gingival fibroblasts, shows enhanced expression by pro-inflammatory cytokines, and stimulates osteoclast differentiation. PLoS ONE 8, e81665.
22. Tian, Y., Shen, H., Xia, L. and Lu, J. (2013) Elevated serum and synovial fluid levels of interleukin-34 in rheumatoid arthritis: possible association with disease progression via interleukin-17 production. J. Interferon Cytokine Res. 33, 398-401.
23. Viennois, E., Chen, F., Laroui, H., Baker, M.T. and Merlin, D. (2013) Dextran sodium sulfate inhibits the activities of both polymerase and reverse transcriptase: lithium chloride purification, a rapid and efficient technique to purify RNA. BMC Res. Notes 6, 360.
24. Huynh, D., Akcora, D., Malaterre, J., Chan, C.K., Dai, X.M., Bertoncello, I., Stanley, E.R. and Ramsay, R.G. (2013) CSF-1 receptor-dependent colon development, homeostasis and inflammatory stress response. PLoS ONE 8, e56951.
25. Wirtz, S., Neufert, C., Weigmann, B. and Neurath, M.F. (2007) Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2, 541-546.
26. Melgar, S., Karlsson, A. and Michaelsson, E. (2005) Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G1328-G1338.
27. Maccioni, F., Viola, F., Carrozzo, F., Di Nardo, G., Pino, A.R., Staltari, I., Al Ansari, N., Vestri, A., Signore, A., Marini, M. et al. (2012) Differences in the location and activity of intestinal Crohn's disease lesions between adult and paediatric patients detected with MRI. Eur. Radiol. 22, 2465-2477.
28. Denning, T.L., Norris, B.A., Medina-Contreras, O., Manicassamy, S., Geem, D., Madan, R., Karp, C.L. and Pulendran, B. (2011) Functional specializations of intestinal dendritic cell and macrophage subsets that control Th17 and regulatory T cell responses are dependent on the T cell/APC ratio, source of mouse strain, and regional localization. J. Immunol. 187, 733-747.
29. MacDonald, T.T., Monteleone, I., Fantini, M.C. and Monteleone, G. (2011) Regulation of homeostasis and inflammation in the intestine. Gastroenterology 140, 1768-1775.
30. Kriegel, C. and Amiji, M. (2011) Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J. Control. Release 150, 77-86.
31. Hanauer, S.B., Feagan, B.G., Lichtenstein, G.R., Mayer, L.F., Schreiber, S., Colombel, J.F., Rachmilewitz, D., Wolf, D.C., Olson, A., Bao, W. et al. (2002) Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549.
32. Cohen, R.D., Tsang, J.F. and Hanauer, S.B. (2000) Infliximab in Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. 95, 3469-3477.
33. Armuzzi, A., De Pascalis, B., Fedeli, P., De Vincentis, F. and Gasbarrini, A. (2008) Infliximab in Crohn's disease: early and long-term treatment. Dig. Liver Dis. 40 (Suppl. 2), S271-S279.
34. D'Haens, G., Baert, F., van Assche, G., Caenepeel, P., Vergauwe, P., Tuynman, H., De Vos, M., van Deventer, S., Stitt, L., Donner, A. et al. (2008) Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371, 660-667.
35. Lichtenstein, G.R., Diamond, R.H., Wagner, C.L., Fasanmade, A.A., Olson, A.D., Marano, C.W., Johanns, J., Lang, Y. and Sandborn, W.J. (2009) Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment. Pharmacol. Ther. 30, 210-226.
36. Panaccione, R., Ghosh, S., Middleton, S., Marquez, J.R., Scott, B.B., Flint, L., van Hoogstraten, H.J., Chen, A.C., Zheng, H., Danese, S. et al. (2014) Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146, 392-400 e393.
37. He, F., Peng, J., Deng, X.L., Yang, L.F., Camara, A.D., Omran, A., Wang, G.L., Wu, L.W., Zhang, C.L. and Yin, F. (2012) Mechanisms of tumor necrosis factor-alpha-induced leaks in intestine epithelial barrier. Cytokine 59, 264-272.
38. Esaki, H., Ewald, D.A., Ungar, B., Rozenblit, M., Zheng, X., Xu, H., Estrada, Y.D., Peng, X., Mitsui, H., Litman, T. et al. (2015) Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J. Allergy Clin. Immunol. 135, 153-163.
39. Wallace, K.L., Zheng, L.B., Kanazawa, Y. and Shih, D.Q. (2014) Immunopathology of inflammatory bowel disease. World J. Gastroenterol. 20, 6-21.
40. Cosmi, L., Liotta, F., Maggi, E., Romagnani, S. and Annunziato, F. (2014) Th17 and non-classic Th1 cells in chronic inflammatory disorders: two sides of the same coin. Int. Arch. Allergy Immunol. 164, 171-177.
41. Qualls, J.E., Kaplan, A.M., van Rooijen, N. and Cohen, D.A. (2006) Suppression of experimental colitis by intestinal mononuclear phagocytes. J. Leukoc. Biol. 80, 802-815.
42. Pull, S.L., Doherty, J.M., Mills, J.C., Gordon, J.I. and Stappenbeck, T.S. (2005) Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc. Natl. Acad. Sci. U.S.A. 102, 99-104.